Mink therapeutics reports clinical and strategic milestones and second quarter 2025 results

New york, aug. 14, 2025 (globe newswire) -- mink therapeutics, inc. (nasdaq: inkt), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer t (inkt) cell therapies, today announced financial results for the second quarter ended june 30, 2025, and provided a business update highlighting major clinical achievements, a strengthened balance sheet, and expanded funding to advance both oncology and immunology programs.
INKT Ratings Summary
INKT Quant Ranking